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Abstract
Background—Childhood asthma has become a critical public health problem because of its high 
morbidity and increasing prevalence. The impact of nutrition and other exposures during 
pregnancy on long-term health and development of children has been of increasing interest.
Objective—We performed a systematic review and meta-analysis of the association of folate and 
folic acid intake during pregnancy and risk of asthma and other allergic outcomes in children.
Design—We performed a systematic search of 8 electronic databases for articles that examined 
the association between prenatal folate or folic acid exposure and risk of asthma and other allergic 
outcomes (eg, allergy, eczema, and atopic dermatitis) in childhood. We performed a meta-analysis 
by using a random-effects model to derive a summary risk estimate of studies with similar 
exposure timing, exposure assessment, and outcomes.
Results—Our meta-analysis provided no evidence of an association between maternal folic acid 
supplement use (compared with no use) in the prepregnancy period through the first trimester and 
asthma in childhood (summary risk estimate: 1.01; 95% CI: 0.78, 1.30). Because of substantial 
heterogeneity in exposures and outcomes, it was not possible to generate summary measures for 
other folate indicators (eg, blood folate concentrations) and asthma or allergy-related outcomes; 
however, the preponderance of primary risk estimates was not elevated.
Conclusions—Our findings do not support an association between periconceptional folic acid 
supplementation and increased risk of asthma in children. However, because of the limited number 
and types of studies in the literature, additional research is needed.
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Asthma is a chronic condition of inflammation and airway constriction that results in clinical 
symptoms, including wheezing and shortness of breath. The diagnosis of asthma has been 
increasing, and in 2010, it has been estimated that asthma affected ~26 million persons in 
the United States, including 9.3% of children (7 million) <18 y of age (1). The diagnosis of 
asthma is based on the presence of signs and symptoms and tests of pulmonary function 
through spirometry (not recommend before 5 y of age) (2, 3). Therefore, a formal asthma 
diagnosis is generally not given to infants and toddlers (3). Children who have had wheezing 
and comorbid conditions such as eczema, atopic dermatitis, and allergic reactions are at 
higher risk to have a later diagnosis of asthma than those without these comorbidities; 
however, 60% of children with wheezing before age 3 y will no longer wheeze at age 6 y (4–
7). It is unclear whether asthma is 1 disorder with many triggers or causes or a group of 
different disorders with similar clinical manifestations.
Causes of asthma are considered to be an interaction of both genetic and environmental risk 
factors. Risk factors for asthma include but are not limited to the following: family history, 
infections in infancy (eg, respiratory syncytial virus), prematurity, fetal growth pattern, 
exposure to pollution and irritants, prenatal and postnatal exposure to cigarette smoke, and 
exposure to allergens (8, 9). Both the immune system and lungs begin development in early 
pregnancy and continue well into childhood (5, 8, 9). This long window of development of 
critical systems allows for a multitude of exposures that could alter asthma risk.
Folate (both natural food folate and synthetic folic acid) is a 1-carbon source critical for the 
replication of DNA and RNA during the cell division and methylation of DNA, histones, and 
other proteins. Clinical folate deficiency is associated with weight loss, slow growth in 
children, and, in severe cases, megaloblastic anemia. In pregnancy, low folate intake (but 
above clinical deficiency) is associated with increased risk of neural tube defects (10), and 
these birth defects are prevented by folic acid supplementation in the periconceptional 
period (before neural tube closure at day 28 of pregnancy) (11). It is recommended that 
women capable of becoming pregnant consume 400 μg folic acid/d (12), and in the United 
States, enriched cereal grain products are fortified (~140 μg folic acid/d) (13). Questions 
have emerged about the role of in utero exposure to folate through maternal intake and the 
development of asthma and atopic disease. In transgenic mice, Hollingsworth et al (14) 
observed that, compared with a lower–methyldonor diet, a diet supplemented with methyl 
donors, including folic acid, choline, L-methionine, and betaine, produced progeny with 
airway hyperactivity, inflammatory response, changes in DNA methylation patterns, and 
reduced gene expression. Although animal models have provided valuable insight, the 
genomic regulation of inflammatory diseases differs substantially between humans and mice 
(15). In humans, wheezing in 4-y-olds has been associated with DNA hypomethylation at 
ALOX12 in their cord blood (16), but it is unknown if maternal folate intake or folic acid 
supplementation during pregnancy changes fetal DNA methylation (17) or risk of asthma. 
The objective of this study was to perform a systematic review and meta-analysis of the 
association between prenatal folate and folic acid exposure and risk of asthma and other 
allergic outcomes in childhood.
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The study was conducted in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement (18). See “supplemental data – protocol” under 
“Supplemental data” in the online issue for our protocol. With the assistance of a research 
librarian, we searched PubMed (http://www.ncbi.nlm.nih.gov/pubmed), Medline (http://
www.ncbi.nlm.nih.gov/), Embase (http://www.embase.com), Cumulative Index to Nursing 
and Allied Health Literature (http://www.ebscohost.com/academic/cinahl-plus-with-full-
text), Cochrane (http://www.thecochranelibrary.com/view/0/index.html), Web of Science 
(http://thomsonreuters.com/web-of-science/), Population Information Online (http://
www.popline.org/), and Education Resources Information Center (http://eric.ed.gov/) for the 
period from the inception of the database through February 2013 by using the term folic acid 
and its variants (folate, folacin, and vitamin B-9) combined with terms specific to allergic 
and respiratory outcomes (eg, asthma, respiratory, wheeze, reactive airway, atopy, and 
allergy) and their associated Medical Subject Headings. To ensure maximum sensitivity, no 
language or other limits were set. See “supplemental data – search strategies” under 
“Supplemental data” in the online issue for full search strategies for each database. We 
scanned reference lists of all included studies as well as those of relevant systematic review 
articles returned in the search, and articles with potentially relevant titles were pulled for 
screening against inclusion criteria.
Inclusion criteria
To be included in the systematic review, studies had to meet the following criteria: 1): be a 
randomized controlled trial, cohort, case-control, or cross-sectional study; 2) report the 
exposure of natural food folate intake, folic acid intake from fortified foods, total folate 
intake from foods (eg, dietary folate equivalents), folic acid intake from supplements, or 
maternal or cord blood serum, plasma, or red blood cell folate concentrations; 3) have an 
exposure timing during the periconceptional period or during pregnancy; 4) provide results 
on at least one allergic or respiratory outcome; and 5) include an evaluation of the direct 
association between folic acid exposure and one of the outcomes of interest.
Two independent reviewers (KSC and AMC) reviewed titles and, when available, the 
abstracts of search results and identified potentially relevant articles (Figure 1). The same 
authors independently reviewed the full text of each potentially relevant article against 
inclusion criteria. There were no discrepancies between authors on articles meriting 
inclusion.
Data extraction
One reviewer (AMC) extracted data into a piloted form, and the extracted data were 
independently cross-checked for accuracy with the original study by 2 additional reviewers 
(KSC and JM). The following elements were extracted: citation, study design (study type, 
study time period, study location, and study name), population (the number of study 
participants), exposure (type, measure, range, cutoffs, and methods of assessment), 
outcomes [type (eg, asthma, wheezing, allergy, eczema, and atopic dermatitis), how defined 
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or measured, and timing], and results [the adjusted RR (aRR)5, adjusted OR (aOR), or 
adjusted prevalence ratio that reflected the greatest degree of control for confounders, CIs, 
and covariates adjusted for in the analysis].
Risk of bias and meta-analysis
We performed meta-analyses on articles with similar exposures and outcomes with 
Comprehensive Meta-Analysis Software (version 2; Biostat). Only the subset of studies of 
periconceptional folic acid exposure (month before and through the first trimester) and risk 
of asthma or wheezing was large enough to perform a meta-analysis of risk (criteria defined 
as ≥3 studies of sufficient quality). We measured the summary effect size for asthma alone 
and performed a sensitivity analysis with asthma combined with wheezing, which is 
sometimes used as a proxy for asthma. We combined the data from cohort studies and 
nested-case control studies by using ORs to approximate RRs. We used a random-effects 
model in our analyses. The risk estimate with the greatest control for confounders from each 
study was used in all analyses; see Supplemental Table 1 under “Supplemental data” in the 
online issue for a list of confounders adjusted for in each study. When risk estimates were 
provided for multiple exposure time points within the periconceptional period, exposure 
timing was prioritized in the following order for inclusion in the quantitative analysis (or 
meta-analysis), to prioritize exposure time periods closest to the DNA methylation 
programing in the early embryo: periconceptional, prepregnancy, and first trimester.
Statistical heterogeneity was tested with the Q statistic and evaluated by using the I2 statistic 
(19), which provides an estimate of the proportion of the variance that is not attributable to 
random error. Heterogeneity was considered to be substantial if I2 was greater than the 
conventional value of 50%. Publication bias was assessed by a visual inspection of funnel 
plots. The trim-and-fill analysis of Duval and Tweedie (20) was used to investigate the 
potential influence that unpublished studies could have on the summary estimates. P < 0.05 
was considered statistically significant in all analyses.
Two authors (KSC and YPQ) independently graded each study included in the meta-analysis 
by using the Newcastle Ottawa Scale (NOS) as recommended by the Cochrane Non-
Randomized Studies Methods Working Group (21). Studies assessed by using the NOS can 
receive a maximum score of 9. For our analyses, studies with a score ≥6 were considered to 
be of sufficient quality to include in the calculation of pooled risk estimates.
RESULTS
The database search produced 1154 articles after deduplication. As shown in Figure 1, after 
a title and abstract review, 34 articles were identified as being potentially relevant for 
inclusion and were reviewed in full. After a full-text review, 12 articles were excluded 
because they were not of appropriate study design (4 commentaries and editorials, 6 
conference highlights, posters, and abstracts, 1 review, and 1 correspondence). Five articles 
were excluded because the assessment of folic acid was of a nonpregnant population. Four 
articles did not evaluate the association between folic acid exposure and one of the outcomes 
5Abbreviations used: aOR, adjusted OR; aRR, adjusted RR; NOS, Newcastle Ottawa Scale
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of interest (eg, asthma, wheeze, or atopy in childhood). Thirteen articles from the database 
search and one article identified through a review of reference lists of potentially relevant 
articles and relevant review articles met inclusion criteria for the systematic review (Figure 
1). Ten of these studies were cohort studies, 3 studies were nested case-control studies, and 1 
study was a case-control study. No randomized controlled trials of folate and folic acid in 
pregnancy and asthma, wheezing, or atopy in childhood were identified. All of the studies 
that met inclusion criteria were published in the English language. The studies reported 
results from 8 different countries.
See Supplemental Table 1 under “Supplemental data” in the online issue for details of the 
characteristics of each individual study. There was substantial heterogeneity in the type of 
folate exposure assessed [ie, folic acid supplements, dietary folate, total folate (supplement 
and diet combined), blood folate concentrations (maternal red blood cell, maternal plasma, 
and cord blood)], the timing of exposure assessment (eg, week or trimester of pregnancy), 
and the measurement method of folate used for analysis [ie, dichotomous (use compared 
with no use), categorical (quantiles of exposure), or continuous (per 100 or 1000 μg/d)]. In 
all studies, dietary folate intake was self-reported via food-frequency questionnaires and 
supplement use was assessed via questionnaires. Outcomes were generally assessed by self-
report of parents in response to a questionnaire (Table 1). All studies included in the review 
that assessed asthma or wheezing did so on the basis of parental response to a questionnaire 
or a structured interview, with the outcome definition varying slightly in studies. Definitions 
for asthma included a parental report of physician-diagnosed asthma, parental report of 
asthma symptoms (at least one attack of wheezing or dyspnea or shortness of breath), child 
ever having taken inhalation medication, or a combination of these items. Studies defined 
wheezing as a parental report of wheezing, whistling, chest tightness, or dyspnea in a 
specified time period (generally the previous 12 mo) (Table 1). Of the 12 studies that 
examined the association between folic acid and asthma or wheeze, only 2 studies also 
looked at clinical test results in addition to a parental report. Both Bekkers et al (27) and 
Magdelijins et al (25) tested for allergic sensitization by measuring IgE in blood samples of 
children and tested their lung function by measuring the forced expiratory volume. The 
timing of the outcome assessment in children ranged from birth to 8 y of age.
Studies were grouped by the timing of folate exposure [early (preconceptional, 
periconceptional, and first trimester) compared with late (second and third trimesters)] 
because widespread demethylation and subsequent remethylation occur in the early embryo, 
and exposures around this time could have different and more widespread effects than in 
later pregnancy (17). In addition, studies were further stratified by association with asthma 
or wheezing (Table 2) or other allergic outcomes (eg, atopy or eczema) (Table 3) and then by 
folate measure (supplementation, dietary, or blood folate) to allow for grouping of related 
measures.
Outcomes: asthma or wheezing in childhood
Exposure: periconceptional or first-trimester use of a supplement containing 
folic acid (yes or no)—Three cohort studies (22–24) and 2 nested case-control studies 
(25, 26) met the inclusion criteria and examined the effect of maternal folic acid supplement 
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use compared with no use (yes or no) in the periconceptional period or first trimester only on 
risk of asthma or wheezing in childhood (Table 2; see Supplemental Table 1 under 
“Supplemental data” in the online issue).
Our meta-analysis of studies (24–26) that analyzed folic acid supplement use as a 
dichotomous variable and reported its association with asthma in childhood showed a pooled 
risk of RR of 1.01 (95% CI: 0.78, 1.30; P = 0.95; I2 = 0.00, P = 0.73) (Figure 2). However, 
the combination of reports of wheezing in infants and toddlers (22, 23) with reports of 
asthma (23, 25, 27) resulted in a significantly elevated summary risk estimate (RR: 1.05; 
95% CI: 1.02, 1.09; P < 0.01; I2 = 0.00, P = 0.68) (Figure 3). The study by Håberg et al (23) 
assessed children at a younger age than did other studies, and its large study population size 
contributed more heavily to the data (Figure 3). The removal of Håberg et al (23) from the 
analysis reduced the summary risk estimate to a nonsignificant level (RR: 1.04; 95% CI: 
0.92, 1.17). A visual inspection of the funnel plot (data not shown) revealed no evidence of a 
publication bias in the literature on folic acid and asthma, although the small number of 
studies was a limitation. When we combined asthma and wheezing in a single meta-analysis, 
the funnel plot suggested some asymmetry (see Supplemental Figure 1 under “Supplemental 
data” in the online issue). According to the trim-and-fill analysis, 1 small study to the right 
of the mean might have been missing. However, the inclusion of this potential study in the 
meta-analysis did not change the summary effect (see Supplemental Figure 1 under 
“Supplemental data” in the online issue). All studies received a score of ≥6 (of a possible 
score of 9) on the NOS in risk of bias assessment (see Supplemental Table 2 under 
“Supplemental data” in the online issue), and thus, sensitivity analyses were not conducted. 
This meta-analysis suggested that the collective literature to date does not support an 
association between periconceptional and first-trimester folic acid supplementation and risk 
of asthma in early childhood.
Exposures: periconceptional and first-trimester folic acid intake other than 
supplement (yes or no), dietary folate intake, and blood folate concentrations
—Five studies (22, 24, 26, 28, 29) examined the association of folate (folic acid use not 
dichotomized as yes or no, dietary folate, or blood folate measurements) in the first trimester 
with childhood asthma or wheezing (12 comparisons); no significantly increased risks were 
reported.
Outcomes: other allergic (eg, atopy, eczema, and atopic dermatitis)
Exposure: periconceptional and first-trimester use of a supplement 
containing folic acid (yes or no)—Many other outcomes are associated with asthma 
risk, such as atopy, eczema, dermatitis and respiratory tract infections. Two cohort studies 
(22, 23), a nested case-control study (25), and a case-control study (34) examined exposure 
to maternal folic acid supplement use compared with no use (yes or no) in the 
periconceptional period or first trimester only and risk of other allergic outcomes (Table 3). 
Of the 13 reported associations across 4 studies, 2 associations in one study reported 
increased risk in 2 outcomes. Håberg et al (23) reported that folic acid supplement use 
(compared with no use) in the first trimester of pregnancy was associated with increased 
risks for lower respiratory tract infections as reported by mothers (aRR: 1.09; 95% CI: 1.02, 
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1.15) and hospitalizations because of lower respiratory tract infections (aRR: 1.24; 95% CI: 
1.09, 1.41) at 0–18 mo of age.
Exposures: periconceptional and first-trimester folic acid intake other than 
supplement (yes or no), dietary folate intake, and blood folate concentrations
—Two cohort studies (22, 28) examined the association of folate (folic acid use not 
dichotomized as yes or no, dietary folate, or blood folate measurements) periconceptionally 
or in the first trimester with other allergic outcomes (Table 3; see Supplemental Table 1 
under “Supplemental data” in the online issue). Of the 3 reported associations across 2 
studies, only 1 association in 1 study reported increased risk. Kiefte de-Jong et al (22) 
showed first-trimester maternal plasma folate concentrations (highest compared with lowest 
quartiles) were associated with increased risk of atopic dermatitis (≤4 y of age) (aOR: 1.18; 
95% CI: 1.05, 1.33).
Outcomes: asthma or wheezing in childhood
Exposures: second- and third-trimester use of a supplement containing folic 
acid (yes or no)—Two cohort studies (23, 27) examined the association between prenatal 
use of a supplement containing folic acid (compared with no use) in the second or third 
trimester and asthma or wheezing in childhood (Table 2; see Supplemental Table 1 under 
“Supplemental data” in the online issue). Of the 15 associations across 2 studies, only one 
association was significantly elevated. Bekkers et al (27) showed that maternal use of folic 
acid in the third trimester was associated with increased risk of maternal report of wheezing 
at 1 y (adjusted prevalence ratio: 1.20; 95% CI: 1.04, 1.39) but not at any time after 1 y of 
age.
Exposures: second- and third-trimester folic acid intake other than 
supplement (yes or no), dietary folate intake, and blood folate concentrations
—Three cohort studies (24, 30, 31) and 2 nested case-control studies (25, 32) examined the 
association between folate (folic acid use not dichotomized as yes or no, dietary folate, or 
blood folate measurements) after the first trimester and childhood asthma or wheezing 
(Table 2). Across the 5 studies and 12 reported associations, 3 associations were significant. 
Håberg et al (32) reported maternal plasma folate concentrations (highest compared with 
lowest quintiles) in the second trimester were associated with increased risk of asthma at age 
3 y (aOR: 1.66; 95% CI: 1.16, 2.37). Whitrow et al (24) showed high-dose folic acid 
supplement use (1000 μg/d) plus dietary folate intake at 30–34 wk of gestation was 
associated with both asthma at 3.5 y (aRR: 1.26; 95% CI: 1.09, 1.47) and persistent asthma 
(defined as asthma at both 3.5 and 5.5 y; aRR: 1.32; 95% CI: 1.03, 1.69) (data not reported 
in Table 2). No significant associations were shown for asthma at 5.5 y (aRR: 1.16; 95% CI: 
0.94, 1.43).
Outcomes: other allergic (eg, atopy, eczema, and atopic dermatitis)
Exposures: second- and third-trimester use of a supplement containing folic 
acid (yes or no)—Three cohort studies (23, 27, 35) examined the use of supplements 
containing folic acid and risk of other allergic outcomes (eg, atopy, eczema, and atopic 
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dermatitis; Table 3). No significant findings were reported across the 38 reported 
associations.
Exposures: second- and third-trimester folic acid intake other than 
supplement (yes or no), dietary folate intake, and blood folate concentrations
—Three cohort studies (30, 31, 35) and 1 nested case-control study (25) examined the 
association of folate (folic acid use not dichotomized as yes or no, dietary folate, or blood 
folate measurements) after the first trimester with other allergic outcomes (Table 3). Two of 
27 reported associations across the 4 studies showed a significant increased risk. Dunstan et 
al (30) showed no associations between cord blood folate and any outcome until the values 
were categorized in tertiles (eg, for logistic regression models). A U-shaped association was 
then shown for cord blood folate and increased risk of sensitization in the third compared 
with second tertiles (aOR: 3.3; 95% CI: 1.3, 8.0) and for the first compared with second 
tertiles (aOR: 2.7; 95% CI: 1.1, 7.0).
Any time or throughout pregnancy
Studies that examined folate at any time in pregnancy (eg, not stratified by the trimester of 
use) or throughout pregnancy are detailed in Tables 2 and 3 (see Supplemental Table 1 under 
“Supplemental data” in the online issue for additional details). Three of the studies showed 
no association (25, 33, 34) between folic acid and any of the outcomes assessed, whereas 
one study (24) showed slight increased risk between folic acid supplement use (compared 
with no use) and wheezing at 6–18 mo of age (aRR: 1.07; 95% CI: 1.02, 1.12) (24).
DISCUSSION
Our systematic review did not support a causal link between the use of folic acid 
supplements during pregnancy and increased risk of asthma in children. Our meta-analysis 
of folic acid supplement use in the periconceptional period through the first trimester and 
asthma in childhood showed no increased risk (summary risk estimate: 1.01; 95% CI: 0.78, 
1.30), although this finding was limited by the small number of studies. Because of the 
substantial heterogeneity in exposures and outcomes, it was not possible to generate 
summary statistics for other folate measures and asthma or allergy-related outcomes; 
however, the preponderance of risk estimates was not elevated (Tables 2 and 3).
Limitations of current literature
One of the significant limitations of the current literature is the lack of randomized clinical 
trials because of ethical issues that would be involved in conducting such a study. 
Randomization of exposure is critical for the assessment of the effect of exposure to 
multivitamin supplements and folic acid supplements because the women who use folic acid 
supplements have different health behaviors and characteristics than do women who do not 
take supplements. Håberg et al (23) observed that supplement users were more likely to have 
atopic conditions, more education, lower smoking rates, and other health-behavior 
differences. Wald and Morris (36) published a reply to the study of Håberg et al (23) and 
argued that the weak association shown in the study was unlikely to be causal and more 
likely a result of confounding because women who are more health conscious are both more 
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likely to take folic acid supplements and to report respiratory problems in their children. 
Other studies also showed that maternal folic acid supplement use was associated with 
maternal self-report of asthma or allergy (22, 26, 35). Several studies reported that children 
with asthma, wheezing, or atopy were significantly more likely to have allergic mothers (29, 
30, 32, 33), and 2 studies reported oversampling of allergic mothers by study design (26, 
30). In addition, Kiefte-de Jong et al (22) reported that mothers who used supplements were 
significantly different from mothers who did not use supplements for 12 of 16 maternal and 
child characteristics including the following: birth weight, parental history of atopy, age, 
ethnicity, education, and smoking and alcohol use during pregnancy. This degree of 
difference was unlikely to be amenable to statistical correction and likely indicative of 
residual confounding because of another unmeasured factor.
Of all of the studies in our review that examined folic acid supplementation, dietary folate 
intake, or blood folate concentrations in the periconceptional period or first trimester and 
risk of asthma or wheezing at any age, the only study with a significant positive association 
was the marginally elevated finding by Håberg et al (23) (aRR: 1.06; CI: 1.03, 1.10). Results 
from the other studies in our review did not confirm this finding (22, 24–26, 28, 29); 
however, none of these studies were of a size that would allow them to detect an estimate so 
modestly elevated.
Limitations of exposure assessment and definition
The determination of how much natural food folate and its synthetic form, folic acid (used in 
multivitamins, prenatal supplements, and food fortification) was consumed is difficult. In 
addition, concerns about recall and self-report can lead to a misclassification of exposure. It 
would be ideal to use a biomarker such as red blood cell or serum folate in mothers or cord 
blood folate to determine folate status. However, not only does this require sampling at the 
critical time of exposure, which precludes its use in retrospective studies and makes very 
large cohort studies difficult, it can also be very costly; hence, there were a limited number 
of studies that used this methodology. In addition, there were a number of different folate 
exposure measures reported (Tables 2 and 3), and it clearly is not possible to combine and 
interpret different exposures measured on different scales to generate a single summary 
estimate.
Limitations of outcome assessment and definition
There is no single diagnostic biomarker of asthma. Symptoms of asthma, such as wheezing, 
are common in infants and young children and, although correlated with increased risk of 
asthma later in life, are often transient (4–7). The single elevated increased risk association 
by Håberg et al (23) was limited to the maternal report of wheezing at the young ages of 6–
18 mo; a substantial portion of these infants and children are unlikely to be diagnosed with 
asthma. This was evident in the studies reviewed in this article, in which an elevated risk of 
asthma or wheezing was reported at some ages but not others (24, 27). In the meta-analysis 
we performed in which reports of wheezing with those of asthma were combined, we 
showed a moderately elevated risk estimate (RR: 1.05; 95% CI: 1.02, 1.09). However, this 
result was driven by the very large cohort assessed in Håberg et al (23) (89% of the summary 
RR weight), and the removal of it from the analysis resulted in a nonsignificant finding (RR: 
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1.04; 95% CI: 0.92, 1.17) (Figure 3). Because of known limitations of the association of 
wheezing in infancy and early toddlerhood with later asthma, the meta-analysis that was 
limited to asthma in children >5 y of age should be considered the more-robust estimate of 
the association of periconceptional folic acid use and asthma risk in childhood.
Limitations of current review
Cohort studies included in the review reported a variety of exposures (eg, folate, folic acid, 
serum folate, red blood cell folate, and cord blood folate), exposure time periods (eg, early 
compared with late pregnancy), and outcomes (eg, wheezing at 6 mo to 6 y of age, asthma 
diagnosis at a variety of ages, allergies, IgE concentrations, and atopy), which rendered the 
question of the association between folic acid exposure in pregnancy and risk of childhood 
asthma difficult to answer. When possible, we attempted to group studies (first-trimester 
supplement use and asthma or wheezing at ages 1–8 y) but fully acknowledge the limitations 
of the summary estimate. To date, the studies could not rule out that higher dosages 
consumed in the third trimester are associated with increased risk in some groups. Note that 
Dunstan et al (30) examined cord blood samples from an Australian cohort (n = 484) and 
reported a U-shaped association with increased risk of sensitization for lower and higher 
tertiles compared with the middle tertile, and no associations were shown when the data 
were not analyzed in this manner. Observed increased risk of both higher and lower cord 
blood could be indicative of an optimal blood folate concentration, although it was 
impossible to determine whether the association was because of other characteristics of 
these groups or a product of multiple testing in a single study.
Research agenda
To fully address the question of a possible association of folic acid supplement use in 
pregnancy and increased risk of asthma in children suggested by the Hollingsworth et al (14) 
animal model, a number of additional studies are warranted. There are at least 3 main 
questions that remain to be answered:
Are there epigenetic changes in utero that are associated with risk of asthma?
Are these epigenetic changes associated with folate or folic acid supplementation at 
specific critical developmental windows during pregnancy?
Is there a dose effect of folate or folic acid (ie, a minimum, maximum, and optimal 
intake) on risk of asthma, wheezing, or allergy-related outcome?
The undertaking of a randomized control trial of the effects of folic acid supplementation in 
pregnancy on allergic outcomes in children would be ideal, although clearly ethically 
problematic. Women would have to be exposed to folic acid supplementation in the 
periconceptional period because of the known benefits for the prevention of neural tube 
defects. An alternative way to address the research questions proposed in this review is to 
use previous trials and follow up the children whose mothers participated in those 
randomized controlled trials in which exposure was randomly assigned. However, the 
original trials were not designed to address many of the questions surrounding the timing of 
supplement use during gestation and may not easily address those hypotheses.
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To circumvent the need for a new randomized controlled tiral, existing cohorts and 
Mendelian random assignment could be used to look for interactions and effects with 
genetic variants involved in one-carbon metabolism and folic acid intake. Some studies have 
looked for associations of risk with 5,10-methylenetetrahydrofolate reductase (MTHFR) (35, 
37), but none to date have looked for the interaction of intake and MTHFR. It is known that 
individuals with the MTHFR677 CC genotype have higher blood folate concentrations for a 
given folic acid intake (17, 38). Because genotype is assigned at birth, it can act as a 
surrogate of randomization. These types of studies require substantial sample sizes to 
achieve a reasonable statistical power. In addition, if the causal pathway is independent of 
the downstream metabolites of folic acid or dietary folate, this approach would be 
ineffective.
In conclusion, the analysis of the published literature to date is difficult to summarize 
because of heterogeneity in folate- and folic acid–exposure windows during pregnancy, a 
variety of asthma and allergy-associated outcomes, and the limited numbers of studies. Our 
meta-analysis does not support the association of folic acid supplement use in the first 
trimester with risk of asthma in childhood.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study selection process flowchart.
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Random-effects meta-analysis of the association between maternal folic acid supplement use 
(compared with no use) in the periconceptional period through the first trimester of 
pregnancy and asthma in childhood. Black squares represent point estimates, and the size of 
each square is proportional to the weight of the study in the analysis. Horizontal lines 
represent CIs. The black diamond represents the summary effect. CC, case-control.
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Random-effects meta-analysis of the association between maternal folic acid supplement use 
(compared with no use) in the periconceptional period through the first trimester of 
pregnancy and asthma or wheezing in childhood. Black squares represent point estimates, 
and the size of each square is proportional to the weight of the study in the analysis. 
Horizontal lines represent CIs. The black diamond represents the summary effect. CC, case-
control.
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TABLE 1








assessment) Definition of outcomes
Kiefte-de Jong et 




~400–500 μg/d First trimester Wheezing (up 
to age 4 y)
Parental report of child having “had 
problems with a wheezing chest during the 
last year” or “problems with tightness of 
the chest or shortness of breath during the 
past year”




No mean or median 
reported; authors 
mentioned 400 μg as a 
recommendation
First trimester Wheezing (at 
6–18 mo)
Maternal report of child having “chest 
congestion/tightness or whistling/wheezing 
in the chest between 6 and 18 months of 
age”
Whitrow et al 
(24); cohort; 490; 
Australia; 1998–
2000
No mean or median 
reported for 
prepregnancy; for 
pregnancy <16 wk, 
medians (ranges) were 
700 μg/d (42.9–5500 
μg/d) at 3.5 y and 
666.6 μg/d (42.9–5500 
μg/d) at 5.5 y of age
Prepregnancy Asthma (3.5 y 
or 5.5 y)
Maternal report of physician-diagnosed 
asthma at 3.5 or 5.5 y




400 μg Periconceptional (−4 to 8 
wk)
Asthma (at 6–7 
y)
“Ever physician diagnosed asthma with 
clinical symptoms [having had at least 1 
attack of wheeze or dyspnea in the past 12 
months] and/or the use of asthma 
medication [everyday use during at least 2 
months or use associated with physical 
activity of short-acting inhalation 
bronchodilators or the use of inhaled 
corticosteroids and medication use 
according to the Dutch guidelines of 
treatment of bronchial asthma in children] 
in the last 12 months”
Wheezing (until 
6–7 y)
Maternal report of child having “suffer[ed] 
from wheezing in the past 12 months” or 
since last follow-up





Mean ± SD: 497 
± 301 μg
First trimester Asthma (at 6 y) Positive maternal response to both of the 
following questions: “Has the child ever 
been diagnosed by a doctor or health 
professional as having asthma?” and “Has 
your child had wheezing or whistling in the 
chest in the past 12 months?”
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